|
gptkbp:instanceOf
|
gptkb:drug
small molecule
|
|
gptkbp:approvalYear
|
2020
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01EX18
|
|
gptkbp:brand
|
gptkb:Pemazyre
|
|
gptkbp:CASNumber
|
1513858-77-6
|
|
gptkbp:chemicalFormula
|
C24H27F2N5O4
|
|
gptkbp:developer
|
gptkb:Incyte_Corporation
|
|
gptkbp:hasSMILES
|
C1=CC(=C(C=C1N2CCN(CC2)C3=NC(=C(C(=N3)C4=CC=C(C=C4)F)N)C(=O)N)F)C(=O)O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
pemigatinib
|
|
gptkbp:KEGGID
|
gptkb:D11741
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
FGFR inhibitor
|
|
gptkbp:molecularWeight
|
480.5 g/mol
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL3989989
DB14894
71546061
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
diarrhea
abdominal pain
constipation
fatigue
alopecia
dry mouth
arthralgia
dysgeusia
hyperphosphatemia
nail toxicity
stomatitis
dry eye
serous retinal detachment
|
|
gptkbp:target
|
gptkb:FGFR3
gptkb:FGFR1
gptkb:FGFR2
|
|
gptkbp:UNII
|
6Z5B6HVF6O
|
|
gptkbp:usedFor
|
cholangiocarcinoma
myeloid/lymphoid neoplasms with FGFR1 rearrangement
|
|
gptkbp:bfsParent
|
gptkb:FGFR1
|
|
gptkbp:bfsLayer
|
6
|